Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017" report to their offering.

Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017 provides comprehensive insights about the treatment landscape across this indication.

This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of The report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages.

This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years.

This recent report covers the treatment landscape which provides the treatment options by different stages and type of the breast cancer. There are four chemotherapy drugs, six hormone therapy drugs and one targeted therapy drugs in market for the treatment of Estrogen Receptor Positive (ER+) Breast Cancer.

Report Highlights:

  • The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape across the globe
  • The report provides profiles of the marketed drug which includes the product description, cost of treatment, development partner, patent expiry date, sales data etc
  • Comparative analysis of marketed drugs by therapy, cost of treatment, Therapeutic Class. Coverage of the Estrogen Receptor Positive (ER+) Breast Cancer Phase III and Pre-registration Drugs Analysis by product type, molecule type, route of administration, Median Progression Free Survival
  • The report reviews key players involved in the therapeutics development for Estrogen Receptor Positive (ER+) Breast Cancer and also provide market barriers, market drivers and opportunities
  • Provides Phase III products assessment by line of therapy and target.

Marketed Products Profile

  • Aromasin (Exmestane)
  • Evista
  • Ibrance
  • Femara
  • Fareston
  • Chemotherapy
  • Halaven
  • Taxotere

Companies Mentioned

  • Curis
  • Genentech
  • Gilead Sciences, Inc.
  • Ipsen
  • Astellas
  • Roche
  • Seattle Genetics
  • Tesaro, Inc.
  • Galena Biopharma

For more information about this report visit http://www.researchandmarkets.com/research/484753/estrogen_receptor

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health